Prostate Cancer Coverage from Every Angle

Multimodal Treatment and Mortality Outcomes in High-Risk Prostate Cancer

By: Kayci Reyer
Posted: Tuesday, September 7, 2021

According to research presented in JAMA Network Open, patients with high-risk prostate cancer and adverse clinicopathologic features who received guideline-concordant multimodal therapy may experience improved survival outcomes. Derya Tilki, MD, of the University Hospital Hamburg-Eppendorf in Germany, and colleagues defined guideline-concordant multimodal treatment as optimal radical prostatectomy, which included the appropriate use of multimodal therapy; optimal external-beam radiotherapy, which included 2 or more years of androgen-deprivation therapy (ADT); or optimal external-beam radiotherapy with a brachytherapy boost, which included 1 or more years of ADT.

The retrospective study included 6,004 men, with an average age of 66.4 years. Patients who received external-beam radiotherapy with (16.6%; n = 999) or without a brachytherapy boost (30.5%; n = 1,830) experienced substantially better disease-specific mortality than did patients who underwent radical prostatectomy (52.9%; n = 3,175; subdistribution hazard ratio [sHR] = 0.78, [95% confidence interval (CI) =, 0.63–0.97]; P  = .03 and sHR = 0.70 [95% CI = 0.53–0.92]; P  = .01, respectively). The addition of a brachytherapy boost to external-beam radiotherapy did not appear to affect disease-specific mortality.

Patients who underwent multimodality therapy (n = 2,940) experienced similar prostate cancer–specific mortality results as those who did not (eg, optimal external-beam radiotherapy vs. optimal radical prostatectomy: sHR = 0.76 [95% CI = 0.52–1.09]; P  = .14). Notably, treatment with external-beam radiotherapy with or without a brachytherapy boost was found to be associated with fewer instances of distant metastasis than was treatment with radical prostatectomy (eg, external-beam radiotherapy alone vs. radical prostatectomy: sHR = 0.50 [95% CI = 0.44–0.58]; P  <  .001).

Disclosure: For full disclosures of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.